ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,948.71
0.53%
US Tech 100
20,172.00
0.22%
Dow Jones
43,870.35
1.06%
Brent Oil
73.835
1.37%
Bitcoin
97,995.82
3.85%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Uniqure Nv (0EE0)

  7. Uniqure Nv (0EE0) News

0EE0

Uniqure Nv (0EE0)

Uniqure Nv
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:0EE0
DateTimeSourceHeadlineSymbolCompany
11/21/20247:05AMUK RegulatoryuniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe EpilepsyLSE:0EE0Uniqure Nv
11/05/20247:05AMUK RegulatoryuniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company ProgressLSE:0EE0Uniqure Nv
10/15/20247:05AMUK RegulatoryuniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALSLSE:0EE0Uniqure Nv
09/23/20247:05AMUK RegulatoryuniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry DiseaseLSE:0EE0Uniqure Nv
08/15/20247:05AMUK RegulatoryuniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry DiseaseLSE:0EE0Uniqure Nv
08/01/20247:05AMUK RegulatoryuniQure Announces Second Quarter 2024 Financial Results and Provides Company UpdateLSE:0EE0Uniqure Nv
07/23/20247:05AMUK RegulatoryuniQure Announces Closing of Sale of Manufacturing Facility to GenezenLSE:0EE0Uniqure Nv
07/09/20247:05AMUK RegulatoryuniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s DiseaseLSE:0EE0Uniqure Nv
07/01/20247:05AMUK RegulatoryuniQure Announces Sale of Commercial Manufacturing Facility to GenezenLSE:0EE0Uniqure Nv
06/03/20247:05AMUK RegulatoryuniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington’s DiseaseLSE:0EE0Uniqure Nv
05/07/20247:05AMUK RegulatoryuniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company ProgressLSE:0EE0Uniqure Nv
02/28/20247:05AMUK RegulatoryuniQure Announces 2023 Financial Results and Highlights Recent Company ProgressLSE:0EE0Uniqure Nv
 Showing the most relevant articles for your search:LSE:0EE0

Your Recent History

NASDAQ
NVDA
NVIDIA
COIN
BTCUSD
Bitcoin
USOTC
TPTW
TPT Global Tech (PK)
USOTC
GDVM
Global Developments (PK)
NASDAQ
SMCI
Super Micro Computer
USOTC
RNVA
Rennova Health (CE)
USOTC
NSAV
Net Savings Link (PK)
USOTC
TGLO
TheGlobe com (PK)
NASDAQ
COOP
Mr Cooper
NYSE
IONQ
IonQ
NASDAQ
QUBT
Quantum Computing
COIN
SHIBUSD
SHIBA INU
NASDAQ
AVXL
Anavex Life Sciences
USOTC
APRU
Apple Rush (PK)
USOTC
DBMM
Digital Brand Media and ... (PK)
NASDAQ
NXPL
NextPlat
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved